COMMERCIAL EXECUTION
SALES DEVELOPMENT ACROSS THERAPEUTIC AREAS
Sales grew by 25% measured in Danish kroner and by 16% at CER in the first six months of 2022, driven by Diabetes care sales growth of 15% (CER) and Obesity care sales growth of 84% (CER). Rare disease sales were unchanged at CER.
| | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
Sales split per therapy | Sales H1 2022 DKK million | Sales H1 2021 DKK million | | Growth as reported | Growth at CER | Share of growth at CER |
Diabetes and Obesity care segment | | | | | | |
| | | | | | | |
| | | | | | | |
Rybelsus® | 4,235 | | 1,674 | | | 153 | % | 134 | % | 21 | % |
Ozempic® | 26,384 | | 14,097 | | | 87 | % | 73 | % | 93 | % |
Victoza® | 6,032 | | 7,606 | | | (21 | %) | (26 | %) | (18 | %) |
| | | | | | | |
Total GLP-1 | 36,651 | | 23,377 | | | 57 | % | 45 | % | 96 | % |
| | | | | | | |
Long-acting insulin | 8,900 | | 8,971 | | | (1 | %) | (6 | %) | (5 | %) |
| - Tresiba® | 4,833 | | 4,557 | | | 6 | % | 0 | % | 0 | % |
| - Xultophy® | 1,408 | | 1,326 | | | 6 | % | 3 | % | 0 | % |
| - Levemir® | 2,659 | | 3,088 | | | (14 | %) | (19 | %) | (5 | %) |
| | | | | | | |
Premix insulin | 5,513 | | 5,668 | | | (3 | %) | (8 | %) | (4 | %) |
| - Ryzodeg® | 1,352 | | 841 | | | 61 | % | 55 | % | 4 | % |
| - NovoMix® | 4,161 | | 4,827 | | | (14 | %) | (19 | %) | (8 | %) |
| | | | | | | |
Fast-acting insulin | 8,729 | | 8,808 | | | (1 | %) | (6 | %) | (5 | %) |
| - Fiasp® | 1,013 | | 837 | | | 21 | % | 16 | % | 1 | % |
| - NovoRapid® | 7,716 | | 7,971 | | | (3 | %) | (9 | %) | (6 | %) |
| | | | | | | |
Human insulin | 4,163 | | 4,576 | | | (9 | %) | (15 | %) | (6 | %) |
| | | | | | | |
Total insulin | 27,305 | | 28,023 | | | (3 | %) | (8 | %) | (20 | %) |
| | | | | | | |
Other Diabetes care1 | 1,714 | | 1,919 | | | (11 | %) | (16 | %) | (3 | %) |
| | | | | | | |
Total Diabetes care | 65,670 | | 53,319 | | | 23 | % | 15 | % | 73 | % |
| | | | | | | |
Wegovy® | 2,585 | | 85 | | | — | | — | | 20 | % |
Saxenda® | 4,460 | | 3,458 | | | 29 | % | 21 | % | 7 | % |
| | | | | | | |
Total Obesity care | 7,045 | | 3,543 | | | 99 | % | 84 | % | 27 | % |
| | | | | | | |
Diabetes and Obesity care total | 72,715 | | 56,862 | | | 28 | % | 19 | % | 100 | % |
| | | | | | | |
Rare disease segment | | | | | | |
Rare blood disorders2 | 5,940 | | 5,401 | | | 10 | % | 3 | % | 2 | % |
| - Haemophilia A | 1,184 | | 1,120 | | | 6 | % | 1 | % | 0 | % |
| - Haemophilia B | 339 | | 309 | | | 10 | % | 6 | % | 0 | % |
| - NovoSeven® | 4,289 | | 3,855 | | | 11 | % | 3 | % | 2 | % |
Rare endocrine disorders3 | 3,743 | | 3,779 | | | (1 | %) | (5 | %) | (2 | %) |
Other Rare disease4 | 898 | | 803 | | | 12 | % | 7 | % | 0 | % |
| | | | | | | |
Rare disease total | 10,581 | | 9,983 | | | 6 | % | 0 | % | 0 | % |
| | | | | | | |
Total sales | 83,296 | | 66,845 | | | 25 | % | 16 | % | 100 | % |
| | | | | | | |
1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®. | | | | |
2) Comprises NovoSeven®, NovoEight®, Esperoct®, Refixia® and NovoThirteen®. | | |
3) Primarily Norditropin®. | | | | |
4) Primarily Vagifem® and Activelle®. |
| | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
DIABETES AND OBESITY CARE
Diabetes care, sales and market share development
Sales in Diabetes care increased by 23% measured in Danish kroner and by 15% at CER to DKK 65,670 million driven by GLP-1 growth. Novo Nordisk has improved the global diabetes value market share over the last 12 months from 29.6% to 31.0% in line with the aspiration of strengthening the Diabetes care leadership, aiming at reaching a global value market share of more than one-third in 2025. The market share increase was driven by market share gains in both International Operations and North America Operations.
In the following sections, unless otherwise noted, market data are based on moving annual total (MAT) from May 2021 and May 2022 provided by the independent data provider IQVIA. EMEA covers Europe, the Middle East and Africa; Region China covers mainland China, Hong Kong and Taiwan, and Rest of World covers all other countries except for North America. | | | | | | | | | | | | | | | | | |
| | | | | |
Diabetes care, development per geographical area | Novo Nordisk’s share of the total diabetes market (value, MAT) | Diabetes care, sales development |
| | | | | |
| | | | | |
| | May | May | Sales H1 2022 DKK million | Growth at CER |
| | 2022 | 2021 |
| | | | | |
| | | | | |
Global | 31.0 | % | 29.6 | % | 65,670 | | 15 | % |
International Operations | 25.8 | % | 24.0 | % | 33,670 | | 10 | % |
| - EMEA * | 29.0 | % | 28.0 | % | 16,734 | | 12 | % |
| - Region China ** | 32.9 | % | 32.7 | % | 8,032 | | (7 | %) |
| - Rest of World *** | 17.5 | % | 14.0 | % | 8,904 | | 25 | % |
North America Operations | 32.8 | % | 31.6 | % | 32,000 | | 21 | % |
| - The US | 32.7 | % | 31.6 | % | 29,742 | | 20 | % |
| | | | | |
| | | | | |
Source: IQVIA, May 2022 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk Diabetes care sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. *** Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk’s Diabetes care sales in the area.
GLP-1 therapy for type 2 diabetes
Sales of GLP-1 products for type 2 diabetes (Rybelsus®, Ozempic® and Victoza®) increased by 57% measured in Danish kroner and by 45% at CER to DKK 36,651 million. The GLP-1 segment’s value share of the total diabetes market has increased to 29.3% compared with 24.0% 12 months ago. Novo Nordisk continues to be the global market leader in the GLP-1 segment with a 54.8% value market share, an increase of 3.3 percentage points compared to 12 months ago. | | | | | | | | | | | | | | | | | |
| | | | | |
GLP-1, development per geographical area | Novo Nordisk's share of the diabetes GLP-1 market (value, MAT) | GLP-1, sales development |
| | | | | |
| | | | | |
| | May | May | Sales H1 2022 DKK million | Growth at CER |
| | 2022 | 2021 |
| | | | | |
| | | | | |
Global | 54.8 | % | 51.5 | % | 36,651 | | 45 | % |
International Operations | 61.3 | % | 56.1 | % | 12,013 | | 53 | % |
| - EMEA * | 59.4 | % | 56.8 | % | 6,815 | | 35 | % |
| - Region China ** | 63.1 | % | 84.7 | % | 1,672 | | 83 | % |
| - Rest of World *** | 66.2 | % | 48.0 | % | 3,526 | | 92 | % |
North America Operations | 53.8 | % | 50.8 | % | 24,638 | | 41 | % |
| - The US | 52.9 | % | 50.1 | % | 23,021 | | 39 | % |
| | | | | |
| | | | | |
Source: IQVIA, May 2022 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk GLP-1 sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. ***Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk Diabetes care sales in the area.
Rybelsus® sales increased by 153% measured in Danish kroner and by 134% at CER to DKK 4,235 million. Sales growth was driven by North America Operations as well as EMEA and Rest of World. Rybelsus® has now been launched in 39 countries.
Ozempic® sales increased by 87% measured in Danish kroner and by 73% at CER to DKK 26,384 million. Sales growth was driven by both North America Operations and International Operations. Ozempic® has been launched in 75 countries.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Victoza® sales decreased by 21% measured in Danish kroner and by 26% at CER to DKK 6,032 million as the GLP-1 market is moving towards once-weekly and tablet-based treatments. The sales decline was driven by both North America Operations and International Operations.
International Operations
Sales of GLP-1 diabetes products in International Operations increased by 60% measured in Danish kroner and by 53% at CER. Sales growth is driven by all geographical areas. The value share of the GLP-1 class of the total diabetes market has increased to 15.5% from 11.9% 12 months ago. Novo Nordisk is the market leader with a value market share of 61.3%.
EMEA
Sales in EMEA increased by 37% measured in Danish kroner and by 35% at CER. The sales growth reflects the uptake of Ozempic® and Rybelsus®, partially offset by lower sales of Victoza®. Rybelsus® has been launched in 32 countries in EMEA. Novo Nordisk remains the market leader in EMEA with a value market share of 59.4%.
Region China
Sales in Region China increased by 101% measured in Danish kroner and by 83% at CER. The sales growth reflects the uptake of Ozempic®, partially offset by lower sales of Victoza®. As of 1 January 2022, Ozempic® has been included on the National Reimbursement List in China. The GLP-1 class' share of the overall diabetes market value in Region China increased to 7.8% from 4.2% 12 months ago.
Rest of World
Sales in Rest of World increased by 103% measured in Danish kroner and by 92% at CER. The sales growth reflects increased sales of Ozempic® and following the Rybelsus® launch in Japan, partially offset by Victoza®. Novo Nordisk remains the market leader with a value market share of 66.2%.
North America Operations
Sales of GLP-1 diabetes products in North America Operations increased by 55% measured in Danish kroner and by 41% at CER. Novo Nordisk is the market leader with a 53.8% value market share compared to 50.8% 12 months ago. The value market share of the GLP-1 class of the total North American diabetes market has increased to 34.0% compared to 28.4% 12 months ago.
Sales growth in the US is driven by a prescription volume growth of the GLP-1 class of more than 35% in the second quarter of 2022 compared to the second quarter of 2021 as well as market share gains for Ozempic® and Rybelsus®. The combined Novo Nordisk GLP-1 new-to-brand prescription market share is now 65.7% driven by Ozempic® with 51.9% and Rybelsus® with 10.1%. Novo Nordisk is the market leader with 56.4% measured on total monthly prescriptions for the combined GLP-1 portfolio.
Sales of GLP-1 in the US increased by 39% at CER. The sales increase was driven by continued uptake of Ozempic® and Rybelsus®, partially offset by declining Victoza® sales. GLP-1 sales growth was negatively impacted by rebate enhancements as well as unfavourable channel and payer mix.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Insulin
Sales of insulin decreased by 3% measured in Danish kroner and by 8% at CER to DKK 27,305 million. Sales decline at CER was driven by declining sales in the US and Region China.
| | | | | | | | | | | | | | | | | |
| | | | | |
Insulin, development per geographical area | Novo Nordisk’s share of the total insulin market (volume, MAT) | Insulin, sales development |
| | | | | |
| | | | | |
| | May | May | Sales H1 2022 DKK million | Growth at CER |
| | 2022 | 2021 |
| | | | | |
| | | | | |
Global | 47.1 | % | 47.2 | % | 27,305 | | (8 | %) |
International Operations | 50.3 | % | 50.2 | % | 20,326 | | (5 | %) |
| - EMEA * | 47.8 | % | 47.5 | % | 9,558 | | 1 | % |
| - Region China ** | 50.5 | % | 50.8 | % | 5,669 | | (17 | %) |
| - Rest of World *** | 57.1 | % | 57.3 | % | 5,099 | | 1 | % |
North America Operations | 38.4 | % | 39.2 | % | 6,979 | | (18 | %) |
| - The US | 37.9 | % | 39.0 | % | 6,411 | | (19 | %) |
| | | | | |
| | | | | |
Source: IQVIA, May 2022 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk insulin sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. ***Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk Diabetes care sales in the area.
International Operations
Sales of insulin in International Operations remained unchanged in Danish kroner and decreased by 5% at CER. The sales decline at CER was driven by lower insulin sales in Region China due to implementation of Volume Based Procurement.
EMEA
Sales of insulin in EMEA increased by 2% measured in Danish kroner and by 1% at CER. The sales growth at CER was mainly driven by Tresiba®, Fiasp® and Ryzodeg®, partially countered by NovoMix®, human insulin, Xultophy® and NovoRapid®. Novo Nordisk has a volume market share of 47.8% of the total insulin market.
Region China
Sales of insulin in Region China decreased by 9% measured in Danish kroner and by 17% at CER. The sales decline was driven by NovoMix®, human insulin, Levemir® and NovoRapid® due to the implementation of Volume Based Procurement from May 2022. The sales decline was partially countered by Ryzodeg®, Tresiba® and Xulthopy®. Novo Nordisk has a volume market share of 50.5% of the total insulin market.
Rest of World
Sales of insulin in Rest of World increased by 7% measured in Danish kroner and by 1% at CER. The sales growth at CER was driven by all insulin products except for human insulin, NovoMix® and Levemir®. Novo Nordisk has a volume market share of 57.1% of the total insulin market.
North America Operations
Sales of insulin in North America Operations decreased by 9% measured in Danish kroner and by 18% at CER. The sales decrease in the US was driven by lower realised prices due to rebate enhancements and channel and payer mix as well as a decline in volume with the US insulin volume market declining 3% compared to the first half of 2021. Novo Nordisk has a volume market share of 37.9% of the total US insulin market.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Obesity care, sales development
Sales of Obesity care products, Saxenda® and Wegovy® increased by 99% measured in Danish kroner and by 84% at CER to DKK 7,045 million. Sales growth was driven by both North America Operations and International Operations. Saxenda® has been launched in 65 countries, and Wegovy® was launched in the US in June 2021. The volume growth of the global branded obesity market was 63%. | | | | | | | | | | | |
| | | |
Obesity care, development per geographical area | Obesity care, sales development |
| | | |
| | | |
| | Sales H1 2022 DKK million | Growth at CER |
| |
| | | |
| | | |
Global | 7,045 | | 84 | % |
International Operations | 2,480 | | 60 | % |
| - EMEA | 1,516 | | 78 | % |
| - Region China | 78 | | — |
| - Rest of World | 886 | | 29 | % |
North America Operations | 4,565 | | 102 | % |
| - The US | 4,345 | | 110 | % |
| | | |
| | | |
International Operations
Sales of Saxenda® in International Operations increased by 66% measured in Danish kroner and by 60% at CER driven by increased sales in EMEA and Rest of World. Novo Nordisk currently has a value market share of 57.8% in the branded obesity prescription drug market.
EMEA
Sales of Saxenda® in EMEA increased by 81% measured in Danish kroner and by 78% at CER. Novo Nordisk currently has a value market share of 79.1% in the branded obesity prescription drug market.
Rest of World
Sales of Saxenda® in Rest of World increased by 38% measured in Danish kroner and by 29% at CER. Saxenda® has been launched in 19 countries in Rest of World. Novo Nordisk currently has a value market share of 44.5% in the branded obesity prescription drug market.
North America Operations
Sales of Obesity care products in North America Operations increased by 123% measured in Danish kroner and by 102% at CER. Novo Nordisk now has a value market share of 92.7% in the branded anti-obesity prescription drug market in North America. Wegovy® was made available to patients in June 2021 and broad commercial formulary access of more than 80% has been achieved.
In December 2021, Novo Nordisk announced that a contract manufacturer filling syringes for Wegovy® pens for the US market temporarily stopped deliveries and manufacturing following issues with current Good Manufacturing Practices. In the second quarter of 2022, the contract manufacturer reinitiated production. The 1.7 mg and the 2.4 mg doses of Wegovy® are currently available in the market and Novo Nordisk expects to make all Wegovy® dose strengths available in the US towards the end of 2022.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Rare disease
Rare disease, sales development
Sales of Rare disease products increased by 6% measured in Danish kroner, and remained unchanged at CER to DKK 10,581 million. | | | | | | | | | | | |
| | | |
Rare disease, development per geographical area | Rare disease, sales development |
| | | |
| | | |
| | Sales H1 2022 DKK million | Growth at CER |
| |
| | | |
| | | |
Global | 10,581 | | 0 | % |
International Operations | 6,453 | | 1 | % |
| - EMEA | 3,489 | | (5 | %) |
| - Region China | 297 | | 58 | % |
| - Rest of World | 2,667 | | 7 | % |
North America Operations | 4,128 | | (1 | %) |
| - The US | 3,787 | | (2 | %) |
| | | |
| | | |
Rare blood disorders
Sales of Rare blood disorder products increased by 10% measured in Danish kroner and by 3% at CER to DKK 5,940 million. The increasing sales were driven by NovoSeven® as well as the launch products Esperoct® and Refixia®.
Sales of haemophilia A products increased by 6% measured in Danish kroner and by 1% at CER to DKK 1,184 million. The sales increase was driven by International Operations, partially countered by North America Operations. Esperoct® has been launched in 27 countries.
Sales of haemophilia B products increased by 10% measured in Danish kroner and by 6% at CER to DKK 339 million. The sales increase was driven by International Operations, partially countered by North America Operations. Refixia® has now been launched in 26 countries.
Sales of NovoSeven® increased by 11% measured in Danish kroner and by 3% at CER to DKK 4,289 million. The sales development was driven by increasing sales in both North America Operations and International Operations.
Rare endocrine disorders
Sales of Rare endocrine disorder products decreased by 1% measured in Danish kroner and by 5% at CER to DKK 3,743 million. The sales decline was driven by North America Operations' sales decreasing by 14% at CER and by International Operations sales decreasing by 1% at CER. The sales decline was driven by lower realised prices in the US and timing of shipments. Novo Nordisk continues being the leading company in the global human growth disorder market with a value market share of 34.0% compared to 32.3% a year ago.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
FINANCIALS
GEOGRAPHIC SALES DEVELOPMENT
Sales increased by 25% measured in Danish kroner and by 16% at CER to DKK 83,296 million in the first six months of 2022. Sales in International Operations increased by 15% measured in Danish kroner and by 10% at CER. The strategic aspiration for International Operations is sales growth between 6-10%. Sales in North America Operations increased by 36% measured in Danish kroner and by 24% at CER. Compared to the strategic aspiration of transforming 70% of sales in the US, 71% of sales are now derived from products launched since 2015.
| | | | | | | | | | | | | | | | | |
| | | | | |
Sales split per geographical area | Sales H1 2022 DKK million | Growth as reported | Growth at CER | Share of growth at CER |
| | | | |
| | | | |
International Operations | 42,603 | | 15 | % | 10 | % | 35 | % |
| - EMEA | 21,739 | | 14 | % | 12 | % | 20 | % |
| - Region China | 8,407 | | 4 | % | (5 | %) | (4 | %) |
| - Rest of World | 12,457 | | 27 | % | 21 | % | 19 | % |
North America Operations | 40,693 | | 36 | % | 24 | % | 65 | % |
| - The US | 37,874 | | 36 | % | 23 | % | 58 | % |
| | | | | |
Total sales | 83,296 | | 25 | % | 16 | % | 100 | % |
International Operations
Sales in International Operations increased by 15% measured in Danish kroner and by 10% at CER. Sales growth was driven by most therapy areas with GLP-1 sales growing by 53% at CER, Obesity care sales growing by 60% at CER and Rare disease sales growing by 1% at CER, partially countered by insulin sales decreasing by 5%.
EMEA
Sales in EMEA increased by 14% measured in Danish kroner and by 12% at CER. Sales growth was driven by Diabetes care growing by 12% at CER driven by increased GLP-1 sales. Obesity care sales increased by 78% at CER and Rare disease sales decreased by 5% at CER.
Region China
Sales in Region China increased by 4% measured in Danish kroner and decreased by 5% at CER. Sales were driven by insulin sales declining by 17% at CER. Insulin sales were negatively impacted by the implementation of Volume Based Procurement from May 2022. GLP-1 sales were growing by 83% at CER and Other diabetes care sales decreased by 25% at CER.
Rest of World
Sales in Rest of World increased by 27% measured in Danish kroner and by 21% at CER. Sales growth was driven by Diabetes care growing by 25% at CER, reflecting increased GLP-1 and insulin sales, Obesity care sales growing by 29% at CER and Rare disease growing by 7% at CER.
North America Operations
Sales in North America Operations increased by 36% measured in Danish kroner and by 24% at CER. The sales increase reflects GLP-1 diabetes sales growing by 41% at CER and Obesity care sales growing by 102% at CER. This was partially offset by insulin sales decreasing by 18% at CER driven by lower realised prices due to rebate enhancements and channel and payer mix as well as a decline in volume. Rare disease sales decreased by 1% at CER.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
DEVELOPMENT IN COSTS AND OPERATING PROFIT
The cost of goods sold increased by 14% measured in Danish kroner and by 12% at CER to DKK 12,986 million, resulting in a gross margin of 84.4% measured in Danish kroner compared with 83.0% in 2021. The increase in gross margin reflects a positive product mix, driven by increased GLP-1 sales, a positive currency impact of 0.8 percentage point and productivity improvements. This is partially countered by lower realised prices mainly in the US.
Sales and distribution costs increased by 29% measured in Danish kroner and by 22% at CER to DKK 21,023 million. The increase in costs is driven by both International Operations and North America Operations. In International Operations, promotional spend is related to launch activities for Ozempic® and Rybelsus® as well as Obesity care market development activities. In North America Operations, the cost increase is driven by promotional activities for Ozempic® and market development activities for Obesity care. The cost increase is reflecting low activity level in 2021 due to COVID-19 and higher distribution costs.
Research and development costs increased by 31% measured in Danish kroner and by 26% at CER to DKK 10,329 million reflecting increased late-stage clinical trial activity compared to the first six months of 2021. Increased activities within Other serious chronic diseases and GLP-1 are driving the cost increase as well as the operating costs and amortisations related to Dicerna Pharmaceuticals Inc. which was acquired in the fourth quarter of 2021.
Administration costs increased by 7% measured in Danish kroner and by 3% at CER to DKK 1,961 million.
Other operating income and expenses (net) was DKK 541 million compared with DKK 255 million in 2021, driven by income from partnerships related to Dicerna Pharmaceuticals Inc.
Operating profit increased by 26% measured in Danish kroner and by 14% at CER to DKK 37,538 million. Operating profit growth was negatively impacted by around 3 percentage points from the acquisition of Dicerna Pharmaceuticals Inc. in 2021.
Financial items (net) showed a net loss of DKK 2,824 million compared with a net gain of DKK 1,094 million in 2021.
In line with Novo Nordisk’s treasury policy, the most significant foreign exchange risks for Novo Nordisk have been hedged, primarily through foreign exchange forward contracts. The foreign exchange result was a net loss of DKK 1,995 million compared with a net gain of DKK 1,049 million in 2021. This reflects losses on hedged currencies, primarily the US dollar.
As per the end of June 2022, a negative market value of financial contracts of approximately DKK 3.5 billion has been deferred for recognition later in 2022 and in 2023.
The effective tax rate was 20.7% in the first six months of 2022 compared with an effective tax rate of 19.8% in 2021 mainly reflecting non-recurring impacts in 2021 from acquisitions.
Net profit increased by 11% to DKK 27,528 million and diluted earnings per share increased by 13% to DKK 12.08.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
KEY DEVELOPMENTS IN THE SECOND QUARTER OF 2022
Sales in the second quarter of 2022 increased by 25% measured in Danish kroner and by 15% at CER compared to the same period in 2021. Operating profit increased by 24% measured in Danish kroner and by 10% at CER.
Please refer to appendix 1 for an overview of the quarterly numbers in DKK and to appendix 6 for additional details on sales in the second quarter of 2022.
| | | | | | | | | | | | | | | | | |
| | | | | |
Sales split per geographical area | Sales Q2 2022 DKK million | Growth as reported | Growth at CER | Share of growth at CER |
| | | | |
| | | | |
International Operations | 20,562 | | 13 | % | 7 | % | 28 | % |
| - EMEA | 10,915 | | 14 | % | 11 | % | 22 | % |
| - Region China | 3,566 | | (4 | %) | (13 | %) | (10 | %) |
| - Rest of World | 6,081 | | 23 | % | 16 | % | 16 | % |
North America Operations | 20,703 | | 40 | % | 24 | % | 72 | % |
| - The US | 19,121 | | 39 | % | 23 | % | 64 | % |
| | | | | |
Total sales | 41,265 | | 25 | % | 15 | % | 100 | % |
The increased global sales of 15% at CER were driven by Diabetes and Obesity care sales as GLP-1 sales increased by 45% at CER, Obesity care sales increased by 66% partially offset by insulin sales decreasing by 13%. Rare disease sales decreased by 2% at CER.
International Operations
Sales in International Operations increased by 13% measured in Danish kroner and by 7% at CER. Sales growth was driven by Region EMEA and Rest of World, partially offset by Region China due to implementation of Volume Based Procurement for insulin.
Sales growth was driven by Diabetes and Obesity care growing by 9% at CER driven by GLP-1 sales growing by 47% at CER, insulin sales decreasing by 10% at CER and Obesity care increasing by 57% at CER. Rare disease sales decreased by 1% at CER.
North America Operations
Sales in North America Operations increased by 40% measured in Danish kroner and by 24% at CER. Sales growth was driven by GLP-1 growing by 44% at CER and Obesity care sales increasing by 72% at CER. Insulin sales decreased by 21% at CER driven by lower realised prices. Rare disease sales decreased by 5% at CER driven by lower NovoSeven® and Norditropin® sales.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
| | | | | | | | | | | | | | | | | | | | |
PROFIT AND LOSS | Q2 2022 | Q2 2021 | | % change Q2 2022 to Q2 2021 | | % change Q2 2022 to Q2 2021 at CER |
| | | | | | |
| | | | | | |
Net sales | 41,265 | 33,041 | | 25 | % | | 15 | % |
| | | | | | |
Gross profit | 35,196 | 27,494 | | 28 | % | | 16 | % |
Gross margin | 85.3% | 83.2% | | | | |
| | | | | | |
Sales and distribution costs | (10,840) | (8,001) | | 35 | % | | 25 | % |
Percentage of sales | 26.3% | 24.2% | | | | |
| | | | | | |
Research and development costs | (5,123) | (3,944) | | 30 | % | | 24 | % |
Percentage of sales | 12.4% | 11.9% | | | | |
| | | | | | |
Administrative costs | (991) | (904) | | 10 | % | | 5 | % |
Percentage of sales | 2.4% | 2.7% | | | | |
| | | | | | |
Other operating income and expenses | 149 | 134 | | 11 | % | | (9 | %) |
| | | | | | |
| | | | | | |
Operating profit | 18,391 | 14,779 | | 24 | % | | 10 | % |
Operating margin | 44.6% | 44.7% | | | | |
| | | | | | |
Financial items (net) | (1,596) | 138 | | N/A | | N/A |
| | | | | | |
| | | | | | |
Profit before income taxes | 16,795 | 14,917 | | 13 | % | | N/A |
| | | | | | |
Income taxes | (3,477) | (2,794) | | 24 | % | | N/A |
Effective tax rate | 20.7% | 18.7% | | | | |
| | | | | | |
Net profit | 13,318 | 12,123 | | 10 | % | | N/A |
Net profit margin | 32.3% | 36.7% | | | | |
| | |
| | |
| | | | | | |
Costs and operating profit
The gross margin was 85.3% in the second quarter of 2022 compared with 83.2% in the same period last year. The 2.1 percentage points gross margin increase reflects a positive product mix, a positive currency impact of 1.0% percentage point, partially countered by lower realised prices in the US.
Sales and distribution costs increased by 35% measured in Danish kroner and by 25% at CER compared with the same period in 2021. The increase was driven by both International Operations and North America Operations reflecting promotional activities related to Ozempic® and Rybelsus® as well as Obesity care market development activities. The cost increase is reflecting low activity level in the second quarter of 2021 due to COVID-19 and higher distribution costs.
Research and development costs increased by 30% measured in Danish kroner and by 24% at CER compared with 2021 driven by increased late-stage clinical trial activities and the operating costs and amortisations related to acquisition of Dicerna Pharmaceuticals Inc.
Administrative costs increased by 10% measured in Danish kroner and by 5% at CER compared with the same period in 2021.
Other operating income and expenses showed an income of DKK 149 million in the second quarter of 2022 compared with an income of DKK 134 million in 2021.
Operating profit increased by 24% measured in Danish kroner and by 10% at CER compared with the same period in 2021.
Financial items (net) showed a net loss of DKK 1,596 million compared with a net gain of DKK 138 million in the second quarter of 2021 reflecting losses on hedged currencies, primarily the US dollar.
The effective tax rate is 20.7% in second quarter of 2022 compared with an effective tax rate of 18.7% in second quarter of 2021 mainly reflecting non-recurring impacts in 2021 from acquisitions.
Net profit increased by 10% to DKK 13,318 million and diluted earnings per share increased by 11% to DKK 5.86.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
CASH FLOW AND CAPITAL ALLOCATION
FREE CASH FLOW IN THE FIRST SIX MONTHS OF 2022 AND CAPITAL EXPENDITURE
Free cash flow was DKK 42.7 billion compared with DKK 32.7 billion in 2021 supporting the strategic aspiration to deliver attractive capital allocation to shareholders. The cash conversion in the first half of 2022 is positively impacted by timing of payment of rebates in the US, including provisions related to the revised 340B distribution policy in the US. Income under the 340B Program has been partially recognised.
Capital expenditure for property, plant and equipment was DKK 4.0 billion compared with DKK 3.1 billion in 2021.
Novo Nordisk’s financial reserves were DKK 42.2 billion by end of June 2022 comprising cash at bank, marketable securities (measured at fair value based on active market data) and undrawn credit facilities less overdrafts and loans repayable within 12 months.
EQUITY AND CAPITAL ALLOCATION
Total equity was DKK 74,452 million at the end of the first six months of 2022, equivalent to 34.0% of total assets, compared with 41.5% at the end of the first six months of 2021. Please refer to appendix 5 for further elaboration of changes in equity.
Novo Nordisk returned DKK 27.6 billion to shareholders via share buyback and dividend during the first half of 2022.
Interim dividend
The Board of Directors has decided to pay out interim dividend for 2022 of DKK 4.25 for each Novo Nordisk A and B
share of DKK 0.20, which will be paid in August 2022. The ex-dividend date for the interim dividend will be 12
August 2022. The record date will be 15 August 2022 for the A and B shares as well as the ADRs. The payment date
for the A and B shares will be 16 August 2022, while the payment date for the ADRs will be 23 August 2022. No
dividend will be paid on the company’s holding of B shares.
2022 share repurchase programme
On 3 May 2022, Novo Nordisk announced a share repurchase programme of up to DKK 4.4 billion to be executed
from 4 May to 2 August 2022, as part of an overall programme of up to DKK 24 billion to be executed during a 12-
month period beginning 2 February 2022. The purpose of the programme was to reduce the company’s share capital
and to meet obligations arising from share-based incentive programmes. Under the programme, Novo Nordisk has
repurchased 5,585,303 B shares for an amount of DKK 4.4 billion in the period from 4 May to 2 August 2022. The
programme was concluded on 2 August 2022.
As of 2 August 2022, Novo Nordisk A/S has repurchased a total of 15,907,432 B shares equal to a transaction value
of DKK 12.202 billion under the DKK 24 billion programme beginning 2 February 2022.
As of 2 August 2022, Novo Nordisk and its wholly-owned affiliates owned 17,647,425 of its own B shares,
corresponding to 0.8% of the total share capital.
The execution of Novo Nordisk’s 2022 share repurchase programme of DKK 24 billion to be executed during a 12-
month period beginning 2 February 2022 continues. As part of this, a new share repurchase programme for an amount up to DKK 4.4 billion will be initiated in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). For that purpose, Novo Nordisk A/S has appointed Skandinaviska Enskilda Banken, Danmark, filial af Skandinaviska Enskilda Banken AB (SEB), as lead manager to execute the programme independently and without influence from Novo Nordisk A/S. The purpose of the programme is to reduce the company’s share capital and to meet obligations arising from share-based incentive programmes. Under the agreement, SEB will repurchase B shares on behalf of Novo Nordisk A/S during the trading period starting, 4 August, and ending on 31 October 2022.
A maximum of 190,000,000 B shares in total can be bought during the trading period. The maximum number of B
shares that can be repurchased on a single trading day may not exceed 20% of the average daily trading volume of
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Novo Nordisk B shares on the trading venue, on which the purchase takes place, during the preceding 20 trading
days of the purchase (excluding the day of the purchase), cf Article 3(3) of the Commission Delegated Regulation
(EU) 2016/1052. At least once every seven trading days, Novo Nordisk A/S will issue an announcement in respect of
the transactions made under the repurchase programme.
As announced in February 2022, Novo Nordisk’s majority shareholder Novo Holdings A/S, a holding company fully owned
by the Novo Nordisk Foundation, has informed Novo Nordisk that it intends to consider its participation in the Novo
Nordisk share repurchase programme on a year-by-year basis. For 2022, Novo Holdings A/S has informed Novo Nordisk
that it plans to participate in the share repurchase programme. Novo Holdings A/S has an ownership of 28.2% of the Novo
Nordisk share capital, and Novo Holdings A/S currently intends to maintain its ownership of the Novo Nordisk share capital around 28%.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
OUTLOOK
OUTLOOK 2022
The current expectations for 2022 are summarised in the table below: | | | | | | | | |
| | |
| | |
Expectations are as reported, if not otherwise stated | Expectations 3 August 2022 | Expectations 29 April 2022 |
| | |
| | |
Sales growth | | |
at CER | 12% to 16% | 10% to 14% |
as reported | Around 9 percentage points higher than at CER | Around 7 percentage points higher than at CER |
| | |
| | |
Operating profit growth | | |
at CER | 11% to 15% | 9% to 13% |
as reported | Around 14 percentage points higher than at CER | Around 11 percentage points higher than at CER |
| | |
| | |
Financial items (net) | Loss of around DKK 5.5 billion | Loss of around DKK 4.1 billion |
| | |
Effective tax rate | 20% to 22% | 20% to 22% |
| | |
Capital expenditure (PP&E) | Around DKK 12.0 billion | Around DKK 12.0 billion |
| | |
Depreciation, amortisation and impairment losses | Around DKK 6.5 billion | Around DKK 6.5 billion |
| | |
Free cash flow (excluding impact from business development) | DKK 57-62 billion | DKK 55-60 billion |
| | |
| | |
For 2022, sales growth is now expected to be 12% to16% at CER. Given the current exchange rates versus the Danish krone, sales growth reported in DKK is now expected to be around 9 percentage points higher than at CER. The guidance reflects expectations for sales growth in both International Operations and North America Operations, mainly driven by Diabetes and Obesity care. Intensifying competition within both Diabetes care and Rare disease as well as an estimated negative impact on global sales growth of around 3 percentage points from Volume Based Procurement of insulin in China are also reflected in the guidance. Furthermore, continued pricing pressure within Diabetes care, especially in the US, is expected to negatively impact sales development. Following higher than expected volume growth, including GLP-1-based products such as Ozempic®, the outlook also reflects expected periodic supply constraints. Finally, the outlook reflects the expectation of making all dose strengths of Wegovy® available in the US towards the end of 2022.
Operating profit growth is now expected to be 11% to 15% at CER. Given the current exchange rates versus the Danish krone, growth reported in DKK is now expected to be around 14 percentage points higher than at CER. The expectation for operating profit growth primarily reflects the updated sales growth outlook and continued investments in future and current growth drivers within Research and Development and Commercial. Across the operating units, commercial investments are related to Ozempic® and Rybelsus® as well as global investments in building the Obesity care market and the launch of Wegovy®. Furthermore, resources are allocated to both early and late-stage pipeline activities. The acquisition of Dicerna Pharmaceuticals Inc. is negatively impacting operating profit growth by around 3 percentage points due to higher operating costs and amortisations of intangible assets.
The potential wider consequences of Russia's invasion of Ukraine, including impacts on energy supply and supply chains, could cause uncertainty to the outlook and the business performance of Novo Nordisk.
For 2022, Novo Nordisk now expects financial items (net) to amount to a loss of around DKK 5.5 billion, mainly reflecting losses associated with foreign exchange hedging contracts.
The effective tax rate for 2022 is still expected to be in the range of 20-22%.
Capital expenditure is still expected to be around DKK 12 billion in 2022 primarily relating to investments in additional capacity for active pharmaceutical ingredient (API) production at existing manufacturing sites.
Depreciation, amortisation and impairment losses are still expected to be around DKK 6.5 billion.
The free cash flow is now expected to be DKK 57-62 billion reflecting higher sales and net profit expectations.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
All of the above expectations are based on assumptions that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during 2022, including energy and supply chain disruptions, the potential implications from major healthcare reforms and legislative changes as well as outcome of legal cases including litigations related to the 340B Drug Pricing Programme in the US, and that the currency exchange rates, especially the US dollar, will remain at the current level versus the Danish krone. Neither does the guidance include the financial implications of any significant business development transactions during the remainder of 2022. | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| | | | | | | |
FX (average rates) | Q2 2022 | Q2 2021 | % change | H1 2022 | H1 2021 | % change | Spot rate 1 August 2022 |
| | | | | | | |
USD | 699 | | 617 | | 13 | % | 681 | | 617 | | 10 | % | 728 | |
CNY | 106 | | 96 | | 10 | % | 105 | | 95 | | 11 | % | 108 | |
JPY | 5.38 | | 5.64 | | (5 | %) | 5.55 | | 5.73 | | (3 | %) | 5.50 | |
CAD | 547 | | 502 | | 9 | % | 535 | | 495 | | 8 | % | 569 | |
GBP | 877 | | 863 | | 2 | % | 883 | | 857 | | 3 | % | 890 | |
| | | | | | | |
| | | | | | | |
Novo Nordisk has hedged expected net cash flows in a number of invoicing currencies and, all other things being equal, movements in key invoicing currencies will impact Novo Nordisk’s operating profit as outlined in the table below. | | | | | | | | |
| | |
| | |
Key invoicing currencies | Impact on Novo Nordisk's operating profit in the next 12 months of a 5% movement in currency | Hedging period (months)1 |
| | |
| | |
USD | DKK 2,950 million | 12 | |
CNY2 | DKK 400 million | 0 |
JPY | DKK 220 million | 12 |
CAD | DKK 250 million | 9 |
GBP | DKK 130 million | 11 | |
| | |
1) As of 1 August 2022.
2) Chinese yuan traded offshore (CNH) used as proxy when hedging Novo Nordisk’s CNY currency exposure.
The financial impact from foreign exchange hedging is included in Financial items (net).
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
INNOVATION AND THERAPEUTIC FOCUS
Diabetes care
Rybelsus® marketing authorisation application submitted in China
In May 2022, Novo Nordisk submitted a new drug application to the China Centre of Drug Evaluation for Rybelsus® for
the treatment of people with insufficiently controlled type 2 diabetes.
Results from phase 3a trials with once-weekly insulin icodec announced
During the second quarter of 2022, Novo Nordisk announced headline results from an additional four 3a trials in the ONWARDS programme with once-weekly insulin icodec. The final trial, ONWARDS 5, will read out in the second half of 2022. For information, please see the company announcements here: https://ml-eu.globenewswire.com/Resource/Download/8b88a207-3143-41bb-83a2-2e7b65c21f33 (The contents of the company's website do not form a part of this Form 6-K), https://ml-eu.globenewswire.com/Resource/Download/6cb10355-bd57-4d0e-8309-9d621fe0bb78 (The contents of the company's website do not form a part of this Form 6-K) and https://ml-eu.globenewswire.com/Resource/Download/618e2f98-af66-4ddb-831a-b9b08a77e2be (The contents of the company's website do not form a part of this Form 6-K).
Phase 1 trial with semaglutide and GIP successfully completed
In May 2022, Novo Nordisk successfully completed a phase 1 trial with a combination of once-weekly semaglutide and GIP. The objective of the trial was to investigate safety and pharmacokinetics of the combination. A phase 2 efficacy trial is expected to complete in the first half of 2023.
Phase 1 trial initiated with an oral once-daily fixed dose combination of GLP-1/SGLT2 inhibitor
In June 2022, Novo Nordisk initiated a phase 1 trial with a fixed dose combination of an oral once-daily GLP-1/SGLT2 inhibitor. The trial is investigating pharmacokinetics of the fixed dose combination compared to each of the mono components.
Obesity care
Wegovy® variant application receives positive opinion by the European Medicines Agency
In June 2022, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the variant application on the FlexTouch® device for Wegovy®. Novo Nordisk expects to receive final marketing authorisation from the European Commission in the third quarter of 2022.
Phase 3b trial successfully completed with semaglutide 2.4 mg in adolescents
In June 2022, Novo Nordisk successfully completed the STEP TEENs trial. The trial was a 68-week double-blind, randomised and placebo-controlled clinical trial comparing semaglutide subcutaneous 2.4 mg once weekly with placebo in 201 pubertal adolescents with obesity or overweight with at least one weight-related comorbidity. The primary endpoint was confirmed with a BMI reduction of 16.1% with semaglutide compared to a reduction of 0.6% for people treated with placebo. In the trial, semaglutide appeared to have a safe and well-tolerated profile.
SELECT cardiovascular outcomes trial continues based on interim analysis
In July 2022, the external independent Data Monitoring Committee (DMC) recommended to continue the SELECT (semaglutide effects on cardiovascular outcomes in people with overweight or obesity) cardiovascular outcomes trial in accordance with the trial protocol. The recommendation follows their review of the interim data. Novo Nordisk does not have access to the actual interim results and the results remain confidential until the completion of the trial. The trial is expected to complete in the middle of 2023.
Phase 1 trial initiated with once-daily oral amycretin
In May 2022, Novo Nordisk initiated a phase 1 trial with oral amycretin, a once-daily GLP-1 and amylin receptor co-agonist. The 12-week trial is investigating safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of oral amycretin in people with overweight or obesity.
Rare disease
Somapacitan submitted for regulatory approval in the EU, the US and Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
In June 2022, Novo Nordisk submitted the long-acting growth hormone somapacitan for regulatory approval for use in children with growth hormone deficiencies in the EU, the US and Japan. The submissions are based on REAL4 results comparing the effect and safety of once-weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency.
Phase 2 trial initiated with NDec in Sickle cell disease
In July 2022, Novo Nordisk initiated a phase 2 trial with NDec, an oral combination of decitabine and tetrahydrouridine. The trial is investigating safety and biomarker efficacy of NDec compared to placebo in 84 adults with sickle cell disease. NDec is licensed from Epidestiny.
Other serious chronic diseases
Phase 2 initiation with NNC6019 in ATTR-cardiomyopathy
In August 2022, Novo Nordisk initiated a phase 2 trial with the anti-amyloid immunotherapy NNC6019. NNC6019 (previously named PRX004) was acquired from Prothena in 2021. The 52-week trial is investigating safety and efficacy of NNC6019 in 99 people with transthyretin amyloid cardiomyopathy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Purpose and sustainability
Environment
| | | | | | | | | | | | | | | | | | | | |
ENVIRONMENTAL PERFORMANCE | H1 2022 | H1 2021 | H1 2019 (pre-COVID)4 | | | | % change H1 2022 to H1 2021 | % change H1 2022 to H1 2019 |
| | | | | | | | |
| | | | | | | | |
Emissions | | | | | | | | |
| | | | | | | | |
CO2 emissions from operations and transportation (1,000 tonnes) | 124 | 83 | 154 | | | | 49 | % | (19 | %) |
- Scope 1 emissions1 | 39 | 36 | 43 | | | | 8 | % | (9 | %) |
- Scope 2 emissions2 | 9 | 9 | 40 | | | | 0 | % | (78 | %) |
- Partial scope 3 emissions3 | 76 | 38 | 71 | | | | 100 | % | 7 | % |
| | | | | | | | |
1. Scope 1: Direct emissions from company owned and controlled resources (including emissions from production processes and transport). 2. Scope 2: Indirect emissions from the generation of energy purchased from a utility provider (including electricity, steam, heat and cooling). 3. Scope 3: Emissions are limited to CO2 emissions from business flights and product distribution. 4. In 2019, some emission categories were only reported at an annual basis. For these categories, the quarterly emissions have been estimated based on the full-year results
| |
| | | | | | | | |
Emissions
Novo Nordisk's ambition is to have zero environmental impact. The environmental strategy is called Circular for Zero.
CO2 emissions from operations and transportation increased by 49% in the first half of 2022 compared to the first half of 2021, mainly reflecting COVID-19 impact on activities in 2021 and increased production volumes. Partial scope 3 emissions doubled compared to the first half of 2021 due to increased business travel and product distribution done by airfreight.
Social
| | | | | | | | | | | | | | |
SOCIAL PERFORMANCE | H1 2022 | H1 2021 | | | | % change H1 2022 to H1 2021 |
| | | | | | |
| | | | | | |
Patients | | | | | | |
Patients reached with Novo Nordisk's Diabetes care products (estimate in million)1 | 35.1 | 33.3 | | | | 5 | % |
'- Hereof children reached through the Changing Diabetes® in Children programme (cumulative) | 34,300 | 29,928 | | | | 15 | % |
| | | | | | |
Sustainable employer | | | | | | |
Gender in leadership positions2 (ratio men:women) | 56:44 | 58:42 | | | | N/A |
Gender in senior leadership positions3 (ratio men:women) | 62:38 | 65:35 | | | | N/A |
| | | | | | |
1. Calculated as a moving annual total. 2. Defined as team leaders, managers, directors, vice presidents, corporate vice presidents, senior vice presidents and executive management. 3. Defined as vice presidents, corporate vice presidents, senior vice presidents and executive management. |
| | | | | | |
Patients
Novo Nordisk continues to take action under the social responsibility strategy ‘Defeat Diabetes’ with a keen focus on access and affordability and prevention. The number of people with diabetes treated with Novo Nordisk products, calculated as a moving annual total, was 35.1 million at the end of June 2022 . This estimated number of people treated represents a net increase of 1.8 million patients compared to the end of June 2021.
Novo Nordisk has the ambition that no child should die from type 1 diabetes. The Changing Diabetes® in Children programme aims to reach 100,000 children by 2030. By end of June 2022, more than 34,000 children were reached, an increase of 15% compared to the first half of 2021. Nigeria has been added to the programme which now includes 24 countries.
With a focus on improving patient access to medicines, Novo Nordisk launched a new multi-stakeholder partnership called Senselet in the second quarter of 2022. Senselet is aimed at ensuring a continuous supply of medicine to patients in Ethiopia by strengthening national supply chain competencies through educational programmes. Senselet will initially run for three years, and the project involves a network of public and private stakeholders, among them the University of Addis Ababa, the Ministry of Health and the Ethiopian Pharmaceutical Supply Services, Kühne Foundation, World Diabetes Foundation and the Geneva Centre of Humanitarian Studies.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Sustainable employer
Novo Nordisk aspires to be a sustainable employer, and in 2021 two aspirational gender diversity targets were launched; achieve a balanced gender representation across all managerial levels and achieve a minimum of 45% women and a minimum of 45% men in senior leadership positions by the end of 2025.
By the end of the second quarter of 2022, 44% of all leaders were women, and 38% of leaders in senior leadership positions were women compared to 42% and 35%, respectively, in the end of second quarter of 2021.
The number of full-time employees at the end of the first six months of 2022 increased by 11% compared to 12 months ago. The total number of full-time employees was 50,816. The increase is driven by Product Supply, International Operations and R&D.
Russia's invasion of Ukraine
Following Russia's invasion of Ukraine, Novo Nordisk's key priorities have been to safeguard employees and continue the supply of essential medicines.
Novo Nordisk offices in Kiev reopened in May 2022 and around half of the employees have voluntarily returned to work. Novo Nordisk has to the extent possible continued supply of medicines in Ukraine and currently, Novo Nordisk medicines are available in more than 90% of Ukraine and Novo Nordisk collaborates with humanitarian organisations to make products available in the residual areas. Moreover, Novo Nordisk has donated five months’ supply of diabetes and haemophilia medication to the Ukrainian Ministry of Health, and together with humanitarian organisations Novo Nordisk continues to monitor the situation to be able to provide further support. In neighbouring countries hosting refugees from Ukraine, Novo Nordisk has provided donations to ensure access to insulin for people who have been forced to flee.
In Russia, Novo Nordisk has suspended further marketing investments, while maintaining supply of medicine to ensure that more than 700,000 patients can continue their treatment with essential medication. Within regulatory, Novo Nordisk has ceased filing for marketing authorisations of new medication, and within clinical development, Novo Nordisk has suspended further clinical investments in Russia. Consequently, no new clinical trials are initiated in Russia, and active enrolment of new patients in ongoing trials is halted. Novo Nordisk's factory in Russia is still operating to supply insulin to patients in Russia only.
Sales in Russia and Ukraine constituted less than 1% of Novo Nordisk's global sales in 2021.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
LEGAL MATTERS
Illinois AG Civil Investigative Demand relating to insulin pricing
On 23 June 2022, Novo Nordisk received a CID from the Attorney General of the State of Illinois calling for information relating to US pricing and trade practices for Novo Nordisk’s diabetes products. The Novo Nordisk products identified in the CID are insulins as well as Victoza® and Ozempic® sold between 2003 and today. Novo Nordisk is cooperating with the Illinois AG’s office in responding to the requests for documents and information in the CID.
Saxenda® Abbreviated New Drug Application litigations in the US
In December 2021, Teva Pharmaceuticals Inc. notified Novo Nordisk that they had filed an Abbreviated New Drug Application (ANDA) for liraglutide, the active pharmaceutical molecule in Saxenda® with the U.S. Food and Drug Administration. Accordingly, the ANDA contains Paragraph IV certifications to obtain approval to engage in the commercial manufacture, use, or sale of Saxenda® before the expiration of some or all of the patents currently listed for Saxenda® in the Orange Book with expiration dates ranging from May 2024–Jul 2037. Subsequently, Orbicular Pharmaceutical Technologies PVT. Ltd, Sun Pharmaceutical Industries Ltd. and Biocon Pharma Limited have provided similar notifications to Novo Nordisk. Novo Nordisk filed complaints for patent infringement against Teva in December 2021, against Orbicular in June 2022 and against Sun and Biocon in July 2022. Novo Nordisk does not expect these matters to have a material impact on Novo Nordisk’s financial position, operating profit or cash flow.
Victoza® Abbreviated New Drug Application litigations in the US
In December 2021, Hikma Pharmaceuticals USA, Inc. notified Novo Nordisk that they had filed an Abbreviated New Drug Application (ANDA) for liraglutide, the active pharmaceutical molecule in Victoza®, with the U.S. Food and Drug Administration. Accordingly, the ANDA contains Paragraph IV certifications to obtain approval to engage in the commercial manufacture, use, or sale of Victoza® before the expiration of some or all of the patents currently listed for Victoza® in the Orange Book with expiration dates ranging from June 2023 to September 2032. Subsequently, Sun Pharmaceutical Industries Ltd. and Biocon Pharma Limited have provided similar notifications to Novo Nordisk. Novo Nordisk filed complaints for patent infringement against Hikma in December 2021 and against Sun and Biocon in July 2022. Novo Nordisk does not expect these matters to have a material impact on Novo Nordisk’s financial position, operating profit or cash flow.
Litigations related to the 340B Drug Pricing Program in the US
Since January 2021, Novo Nordisk has changed its policy in the US related to the 340B Drug Pricing Program, whereby Novo Nordisk no longer provides 340B statutory discounts to certain pharmacies that contract with covered entities participating in the 340B Drug Pricing Program. Novo Nordisk’s contract pharmacy policy has been challenged by the US Department of Health and Human Services. On 17 May 2021, the US government issued a letter to Novo Nordisk asserting that Novo Nordisk’s policy violates the 340B statute. Novo Nordisk believes its policy does not violate the 340B Drug Pricing Program requirements and has commenced litigation against the government seeking a declaration that its 340B policy is consistent with relevant US laws. On 5 November 2021, the US District Court for the District of New Jersey issued a decision on Novo Nordisk’s motion for summary judgment holding that the use of contract pharmacies is consistent with the 340B statute and that manufacturers have no statutory right to impose restrictions on the sale or distribution of 340B drugs. Novo Nordisk has appealed the decision to the US Court of Appeals for the Third Circuit. A decision on this appeal is now expected in the first half of 2023. Depending on the outcome of these matters, there may be a significant impact on Novo Nordisk’s financial position, net sales and cash flow.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
MANAGEMENT STATEMENT
The Board of Directors and Executive Management have reviewed and approved the financial report of Novo Nordisk A/S
for the first six months of 2022. The financial report has not been audited or reviewed by the company’s
independent auditors.
The financial report for the first six months of 2022 has been prepared in accordance with IAS 34 'Interim Financial
Reporting' and additional Danish disclosure requirements for listed companies. The accounting policies adopted in the
preparation are consistent with those applied in the Annual Report 2021 of Novo Nordisk.
In our opinion, the financial report for the first six months of 2022 gives a true and fair view of the Group’s assets,
liabilities and financial position at 30 June 2022, and of the results of the Group’s operations and cash flow for the
period 1 January 2022 to 30 June 2022. Furthermore, in our opinion, Management’s Review includes a true and fair
account of the development in the operations and financial circumstances of the results for the period and of the financial
position of the Group as well as a description of the most significant risks and elements of uncertainty facing the Group in
accordance with Danish disclosure requirements for listed companies.
Besides what has been disclosed in the quarterly financial report, no changes in the Group’s most significant risks and
uncertainties have occurred relative to what was disclosed in the consolidated Annual Report 2021.
Bagsværd, 3 August 2022 | | | | | | | | |
Executive Management: | | |
| | |
Lars Fruergaard Jørgensen President and CEO | Karsten Munk Knudsen CFO | Monique Carter |
| | |
Martin Holst Lange | Marcus Schindler | Camilla Sylvest |
| | |
Henrik Wulff | | |
| | |
Board of Directors: | | |
| | |
Helge Lund Chair | Henrik Poulsen Vice chair | Jeppe Christiansen |
| | |
Elisabeth Dahl Christensen | Laurence Debroux | Andreas Fibig |
| | |
Sylvie Grégoire | Liselotte Hyveled | Mette Bøjer Jensen |
| | |
Kasim Kutay | Christina Law | Martin Mackay |
| | |
Thomas Rantzau | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
| | | | | |
Financial calendar | |
2 November 2022 | Financial statement for the first nine months of 2022 |
1 February 2023 | Financial statement for 2022 |
| | | | | | | | |
Contacts for further information | |
Media: | | |
Ambre Brown Morley | +45 3079 9289 | abmo@novonordisk.com |
Natalia Salomao Abrahao (US) | +1 848 304 1027 | niaa@novonordisk.com |
| | |
Investors: | | |
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
David Heiberg Landsted | +45 3077 6915 | dhel@novonordisk.com |
Jacob Martin Wiborg Rode | +45 3075 5956 | jrde@novonordisk.com |
Mark Joseph Root (US) | +1 848 213 3219 | mjhr@novonordisk.com |
Further information about Novo Nordisk is available on novonordisk.com.
Forward-looking statements
Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s statutory Annual Report 2021 and Form 20-F both filed with the SEC in February 2022 in continuation of the publication of the Annual Report 2021, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:
•statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,
•statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,
•statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
•statements regarding the assumptions underlying or relating to such statements.
In this document, examples of forward-looking statements can be found under the headings ‘Outlook’, ‘Research and Development update’ and 'Equity’.
These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this document, could cause actual results to differ materially from those contemplated in any forward-looking statements.
Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, such as interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result of interruptions or delays affecting supply chains on which Novo Nordisk relies, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology including the risk of cybersecurity breaches, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, failure to maintain a culture of compliance, epidemics, pandemics or other public health crises, and the effects of domestic or international crises, civil unrest, war or other conflict, and factors related to the foregoing matters and other factors not specifically identified herein.
For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or the accuracy of forward-looking statements in this document, reference is made to the overview of risk factors in ‘Risk Management’ of the Annual Report 2021.
Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 1: QUARTERLY NUMBERS IN DKK | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | |
(Amounts in DKK million, except number of full-time equivalent employees, earnings per share and number of shares outstanding). |
| | | | | | | | | | | % change |
| | | 2022 | | 2021 | | Q2 2022 vs. |
| | | Q2 | Q1 | | Q4 | Q3 | Q2 | Q1 | | Q2 2021 |
| | | | | | | | | | | |
| | | | | | | | | | | |
Net sales | | | 41,265 | 42,031 | | 38,333 | 35,622 | 33,041 | 33,804 | | 25 | % |
| | | | | | | | | | | |
Gross profit | | | 35,196 | 35,114 | | 32,092 | 29,563 | 27,494 | 27,993 | | 28 | % |
Gross margin | | | 85.3% | 83.5% | | 83.7% | 83.0% | 83.2% | 82.8% | | |
| | | | | | | | | | | |
Sales and distribution costs | | | (10,840) | (10,183) | | (11,632) | (9,119) | (8,001) | (8,256) | | 35 | % |
Percentage of sales | | | 26.3% | 24.2% | | 30.3% | 25.6% | 24.2% | 24.4% | | |
Research and development costs | | | (5,123) | (5,206) | | (5,632) | (4,252) | (3,944) | (3,944) | | 30 | % |
Percentage of sales | | | 12.4% | 12.4% | | 14.7% | 11.9% | 11.9% | 11.7% | | |
Administrative costs | | | (991) | (970) | | (1,190) | (1,024) | (904) | (932) | | 10 | % |
Percentage of sales | | | 2.4% | 2.3% | | 3.1% | 2.9% | 2.7% | 2.8% | | |
Other operating income and expenses | | | 149 | 392 | | (4) | 81 | 134 | 121 | | 11 | % |
| | | | | | | | | | | |
Operating profit | | | 18,391 | 19,147 | | 13,634 | 15,249 | 14,779 | 14,982 | | 24 | % |
Operating margin | | | 44.6% | 45.6% | | 35.6% | 42.8% | 44.7% | 44.3% | | |
| | | | | | | | | | | |
Financial income | | | 1,656 | 210 | | 254 | 790 | 90 | 1,753 | | 1,740 | % |
Financial expenses | | | (3,252) | (1,438) | | (775) | (927) | 48 | (797) | | (6,875 | %) |
Financial items (net) | | | (1,596) | (1,228) | | (521) | (137) | 138 | 956 | | (1,257 | %) |
| | | | | | | | | | | |
Profit before income taxes | | | 16,795 | 17,919 | | 13,113 | 15,112 | 14,917 | 15,938 | | 13 | % |
| | | | | | | | | | | |
Income taxes | | | (3,477) | (3,709) | | (2,221) | (2,993) | (2,794) | (3,315) | | 24 | % |
| | | | | | | | | | | |
Net profit | | | 13,318 | 14,210 | | 10,892 | 12,119 | 12,123 | 12,623 | | 10 | % |
| | | | | | | | | | | |
Depreciation, amortisation and impairment losses | | | 1,636 | 1,650 | | 2,082 | 1,349 | 1,217 | 1,377 | | 34 | % |
Capital expenditure (PP&E) | | | 2,435 | 1,520 | | 2,049 | 1,175 | 1,709 | 1,402 | | 42 | % |
Net cash generated from operating activities | | | 23,961 | 23,586 | | (3,017) | 21,507 | 25,255 | 11,255 | | (5 | %) |
Free cash flow | | | 21,157 | 21,568 | | (22,993) | 19,616 | 23,164 | 9,532 | | (9 | %) |
| | | | | | | | | | | |
Total assets | | | 218,928 | 197,136 | | 194,508 | 174,084 | 158,095 | 141,387 | | 38 | % |
Total equity | | | 74,452 | 66,550 | | 70,746 | 66,112 | 65,559 | 58,496 | | 14 | % |
Equity ratio | | | 34.0% | 33.8% | | 36.4% | 38.0% | 41.5% | 41.4% | | |
| | | | | | | | | | | |
Full-time equivalent employees end of period | | | 50,816 | 49,295 | | 47,792 | 46,982 | 45,971 | 45,157 | | 11 | % |
| | | | | | | | | | | |
Basic earnings per share/ADR (in DKK) | | | 5.87 | 6.24 | | 4.77 | 5.29 | 5.26 | 5.47 | | 12 | % |
Diluted earnings per share/ADR (in DKK) | | | 5.86 | 6.22 | | 4.76 | 5.27 | 5.26 | 5.45 | | 11 | % |
Average number of shares outstanding (million) | | | 2,269.2 | 2,276.4 | | 2,284.0 | 2,291.9 | 2,300.8 | 2,309.6 | | (1 | %) |
Average number of diluted shares outstanding (million) | | | 2,276.1 | 2,283.3 | | 2,290.6 | 2,297.3 | 2,306.3 | 2,315.6 | | (1 | %) |
| | | | | | | | | | | |
Sales by business segment: | | | | | | | | | | | |
Total GLP-1 | | | 19,231 | 17,420 | | 16,372 | 13,848 | 12,077 | 11,300 | | 59 | % |
Long-acting insulin | | | 4,104 | 4,796 | | 4,677 | 4,416 | 4,149 | 4,822 | | (1 | %) |
Premix insulin | | | 2,501 | 3,012 | | 2,691 | 2,844 | 2,715 | 2,953 | | (8 | %) |
Fast-acting insulin | | | 3,887 | 4,842 | | 4,520 | 4,359 | 4,252 | 4,556 | | (9 | %) |
Human insulin | | | 1,851 | 2,312 | | 2,085 | 2,391 | 2,041 | 2,535 | | (9 | %) |
Total insulin | | | 12,343 | 14,962 | | 13,973 | 14,010 | 13,157 | 14,866 | | (6 | %) |
Other Diabetes care | | | 830 | 884 | | 816 | 859 | 809 | 1,110 | | 3 | % |
Total Diabetes care | | | 32,404 | 33,266 | | 31,161 | 28,717 | 26,043 | 27,276 | | 24 | % |
Wegovy® | | | 1,181 | 1,404 | | 782 | 519 | 85 | — | | — |
Saxenda® | | | 2,462 | 1,998 | | 1,677 | 1,879 | 1,907 | 1,551 | | 29 | % |
Total Obesity care | | | 3,643 | 3,402 | | 2,459 | 2,398 | 1,992 | 1,551 | | 83 | % |
Diabetes and Obesity care total | | | 36,047 | 36,668 | | 33,620 | 31,115 | 28,035 | 28,827 | | 29 | % |
| | | | | | | | | | | |
Rare blood disorders | | | 2,863 | 3,077 | | 2,490 | 2,326 | 2,723 | 2,678 | | 5 | % |
Rare endocrine disorders | | | 1,923 | 1,820 | | 1,719 | 1,805 | 1,859 | 1,920 | | 3 | % |
Other Rare disease | | | 432 | 466 | | 504 | 376 | 424 | 379 | | 2 | % |
Rare disease total | | | 5,218 | 5,363 | | 4,713 | 4,507 | 5,006 | 4,977 | | 4 | % |
| | | | | | | | | | | |
Sales by geographic segment: | | | | | | | | | | | |
International Operations | | | 20,562 | 22,041 | | 18,216 | 18,337 | 18,237 | 18,747 | | 13 | % |
- EMEA | | | 10,915 | 10,824 | | 9,427 | 9,170 | 9,579 | 9,530 | | 14 | % |
- Region China | | | 3,566 | 4,841 | | 3,710 | 4,257 | 3,722 | 4,330 | | (4 | %) |
- Rest of World | | | 6,081 | 6,376 | | 5,079 | 4,910 | 4,936 | 4,887 | | 23 | % |
North America Operations | | | 20,703 | 19,990 | | 20,117 | 17,285 | 14,804 | 15,057 | | 40 | % |
- The US | | | 19,121 | 18,753 | | 18,902 | 16,181 | 13,754 | 14,172 | | 39 | % |
| | | | | | | | | | | |
Segment operating profit: | | | | | | | | | | | |
Diabetes and Obesity care | | | 15,873 | 16,379 | | 11,861 | 13,052 | 12,155 | 12,470 | | 31 | % |
Rare disease | | | 2,518 | 2,768 | | 1,773 | 2,197 | 2,624 | 2,512 | | (4 | %) |
| | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 2: INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | |
| | | | | | | |
DKK million | H1 2022 | | H1 2021 | | Q2 2022 | | Q2 2021 |
| | | | | | | |
| | | | | | | |
Income statement | | | | | | | |
| | | | | | | |
Net sales | 83,296 | | 66,845 | | 41,265 | | 33,041 |
Cost of goods sold | (12,986) | | (11,358) | | (6,069) | | (5,547) |
| | | | | | | |
| | | | | | | |
Gross profit | 70,310 | | 55,487 | | 35,196 | | 27,494 |
| | | | | | | |
Sales and distribution costs | (21,023) | | (16,257) | | (10,840) | | (8,001) |
Research and development costs | (10,329) | | (7,888) | | (5,123) | | (3,944) |
Administrative costs | (1,961) | | (1,836) | | (991) | | (904) |
Other operating income and expenses | 541 | | 255 | | 149 | | 134 |
| | | | | | | |
| | | | | | | |
Operating profit | 37,538 | | 29,761 | 29761000000 | 18,391 | | 14,779 |
| | | | | | | |
Financial income | 1,866 | | 1,843 | | 1,656 | | 90 |
Financial expenses | (4,690) | | (749) | | (3,252) | | 48 |
| | | | | | | |
| | | | | | | |
Profit before income taxes | 34,714 | | 30,855 | | 16,795 | | 14,917 |
| | | | | | | |
Income taxes | (7,186) | | (6,109) | | (3,477) | | (2,794) |
| | | | | | | |
| | | | | | | |
NET PROFIT | 27,528 | | 24,746 | 24746000000 | 13,318 | | 12,123 |
| | | | | | | |
| | | | | | | |
Basic earnings per share (DKK) | 12.11 | | 10.73 | | 5.87 | | 5.26 |
Diluted earnings per share (DKK) | 12.08 | | 10.71 | | 5.86 | | 5.26 |
| | | | | | | |
Segment Information | | | | | | | |
| | | | | | | |
| | | | | | | |
Segment sales: | | | | | | | |
Diabetes and Obesity care | 72,715 | | 56,862 | | 36,047 | | 28,035 |
Rare disease | 10,581 | | 9,983 | | 5,218 | | 5,006 |
| | | | | | | |
Segment operating profit: | | | | | | | |
Diabetes and Obesity care | 32,252 | | 24,625 | | 15,873 | | 12,155 |
Operating margin | 44.4% | | 43.3% | | 44.0% | | 43.4% |
| | | | | | | |
Rare disease | 5,286 | | 5,136 | | 2,518 | | 2,624 |
Operating margin | 50.0% | | 51.4% | | 48.3% | | 52.4% |
| | | | | | | |
Total segment operating profit | 37,538 | | 29,761 | | 18,391 | | 14,779 |
| | | | | | | |
| | | | | | | |
Statement of comprehensive income | | | | | | | |
| | | | | | | |
Net profit for the period | 27,528 | | 24,746 | | 13,318 | | 12,123 |
| | | | | | | |
Other comprehensive income | | | | | | | |
Items that will not subsequently be reclassified to the Income statement | | | | | | | |
Remeasurements on defined benefit plans | 677 | | 196 | | 352 | | (17) |
| | | | | | | |
Items that will be reclassified subsequently to the Income statement | | | | | | | |
Exchange rate adjustments of investments in subsidiaries | 4,014 | | 529 | | 2,927 | | (74) |
Cash flow hedges, realisation of previously deferred (gains)/losses | 1,269 | | (1,410) | | 628 | | (434) |
Cash flow hedges, deferred gains/(losses) incurred during the period | (3,053) | | (813) | | (2,401) | | 760 |
Other items | (2) | | (2) | | 2 | | — |
Tax on other comprehensive income, income/(expense) | 319 | | 528 | | 194 | | (69) |
| | | | | | | |
Other comprehensive income for the period, net of tax | 3,224 | | (972) | | 1,702 | | 166 |
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD | 30,752 | | 23,774 | | 15,020 | | 12,289 |
| | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 3: CASH FLOW STATEMENT | | | | | | | | | | | |
| | | |
DKK million | H1 2022 | | H1 2021 |
| | | |
| | | |
Net profit | 27,528 | | | 24,746 | |
| | | |
Adjustment for non-cash items: | | | |
Income taxes in the Income Statement | 7,186 | | | 6,109 | |
Depreciation, amortisation and impairment losses | 3,286 | | | 2,594 | |
Other non-cash items | 11,805 | | | 9,172 | |
Change in working capital | 5,982 | | | 1,739 | |
Interest received | 109 | | | 43 | |
Interest paid | (120) | | | (85) | |
Income taxes paid | (8,229) | | | (7,808) | |
| | | |
| | | |
Net cash generated from operating activities | 47,547 | | | 36,510 | |
| | | |
| | | |
Purchase of intangible assets | (400) | | | (272) | |
| | | |
Purchase of property, plant and equipment | (3,955) | | | (3,111) | |
| | | |
Proceeds from other financial assets | — | | | 3 | |
Purchase of other financial assets | (7) | | | (4) | |
Purchase of marketable securities | (4,904) | | | (3,755) | |
Sale of marketable securities | 3,159 | | | 768 | |
| | | |
| | | |
Dividend received from associated company | — | | | 4 | |
| | | |
| | | |
Net cash used in investing activities | (6,107) | | | (6,367) | |
| | | |
| | | |
Purchase of treasury shares | (11,927) | | | (8,400) | |
Dividends paid | (15,690) | | | (13,496) | |
Proceeds from issue of bonds | 11,120 | | | 9,657 | |
Proceeds from borrowings | 30 | | | — | |
Repayment of borrowings | (13,099) | | | (6,072) | |
| | | |
| | | |
| | | |
Net cash used in financing activities | (29,566) | | | (18,311) | |
| | | |
| | | |
NET CASH GENERATED FROM ACTIVITIES | 11,874 | | | 11,832 | |
| | | |
Cash and cash equivalents at the beginning of the year | 10,719 | | | 12,226 | |
| | | |
Exchange gain/(loss) on cash and cash equivalents | 163 | | | 169 | |
| | | |
| | | |
Cash and cash equivalents at the end of the period | 22,756 | | | 24,227 | |
| | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 4: BALANCE SHEET | | | | | | | | | | | |
| | | |
DKK million | 30 Jun 2022 | | 31 Dec 2021 |
| | | |
| | | |
ASSETS | | | |
| | | |
Intangible assets | 44,590 | | | 43,171 | |
Property, plant and equipment | 59,556 | | | 55,362 | |
Investments in associated companies | 463 | | | 525 | |
Deferred income tax assets | 10,309 | | | 8,672 | |
Other receivables and prepayments | 252 | | | 267 | |
Other financial assets | 779 | | | 916 | |
| | | |
| | | |
TOTAL NON-CURRENT ASSETS | 115,949 | | | 108,913 | |
| | | |
Inventories | 21,706 | | | 19,621 | |
Trade receivables | 40,826 | | | 40,643 | |
Tax receivables | 1,168 | | | 1,119 | |
Other receivables and prepayments | 4,645 | | | 5,037 | |
Marketable securities | 8,279 | | | 6,765 | |
Derivative financial instruments | 3,597 | | | 1,690 | |
Cash at bank | 22,758 | | | 10,720 | |
| | | |
TOTAL CURRENT ASSETS | 102,979 | | | 85,595 | |
TOTAL ASSETS | 218,928 | | | 194,508 | |
| | | |
EQUITY AND LIABILITIES | | | |
| | | |
Share capital | 456 | | | 462 | |
Treasury shares | (3) | | | (6) | |
Retained earnings | 73,166 | | | 72,004 | |
Other reserves | 833 | | | (1,714) | |
| | | |
| | | |
TOTAL EQUITY | 74,452 | | | 70,746 | |
| | | |
Borrowings | 24,178 | | | 12,961 | |
Deferred income tax liabilities | 5,217 | | | 5,271 | |
Retirement benefit obligations | 617 | | | 1,280 | |
Other liabilities | 167 | | | 360 | |
Provisions | 4,642 | | | 4,374 | |
| | | |
| | | |
Total non-current liabilities | 34,821 | | | 24,246 | |
| | | |
Borrowings | 1,256 | | | 13,684 | |
Trade payables | 14,654 | | | 8,870 | |
Tax payables | 3,943 | | | 3,658 | |
Other liabilities | 19,631 | | | 19,600 | |
Derivative financial instruments | 4,383 | | | 2,184 | |
Provisions | 65,788 | | | 51,520 | |
| | | |
| | | |
Total current liabilities | 109,655 | | | 99,516 | |
| | | |
TOTAL LIABILITIES | 144,476 | | | 123,762 | |
| | | |
TOTAL EQUITY AND LIABILITIES | 218,928 | | | 194,508 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 5: EQUITY STATEMENT | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | |
DKK million | Share capital | Treasury shares | Retained earnings | | | | Other reserves | | Total |
| | | | | | | | | |
| | | | | | | | | |
H1 2022 | | | | | | | | | |
| | | | | | | | | |
Balance at the beginning of the period | 462 | | (6) | | 72,004 | | | | | (1,714) | | | 70,746 | |
Net profit for the period | | | 27,528 | | | | | | | 27,528 | |
Other comprehensive income for the period | | | 677 | | | | | 2,547 | | | 3,224 | |
| | | | | | | | | |
| | | | | | | | | |
Total comprehensive income for the period | | | 28,205 | | | | | 2,547 | | | 30,752 | |
| | | | | | | | | |
| | | | | | | | | |
Transactions with owners: | | | | | | | | | |
Dividends | | | (15,690) | | | | | | | (15,690) | |
Share-based payments | | | 501 | | | | | | | 501 | |
Tax related to restricted stock units | | | 70 | | | | | | | 70 | |
Purchase of treasury shares | | (3) | | (11,924) | | | | | | | (11,927) | |
Reduction of the B share capital | (6) | | 6 | | | | | | | | — | |
| | | | | | | | | |
Balance at the end of the period | 456 | | (3) | | 73,166 | | | | | 833 | | | 74,452 | |
| | | | | | | | | |
|
| | | | | | | | |
DKK million | Share capital | Treasury shares | Retained earnings | | | | Other reserves | | Total |
| | | | | | | | | |
| | | | | | | | | |
H1 2021 | | | | | | | | | |
| | | | | | | | | |
Balance at the beginning of the period | 470 | | (8) | | 63,774 | | | | | (911) | | | 63,325 | |
Net profit for the period | | | 24,746 | | | | | | | 24,746 | |
Other comprehensive income for the period | | | 196 | | | | | (1,168) | | | (972) | |
| | | | | | | | | |
| | | | | | | | | |
Total comprehensive income for the period | | | 24,942 | | | | | (1,168) | | | 23,774 | |
| | | | | | | | | |
| | | | | | | | | |
Transactions with owners: | | | | | | | | | |
Dividends | | | (13,496) | | | | | | | (13,496) | |
Share-based payments | | | 371 | | | | | | | 371 | |
Tax related to restricted stock units | | | (15) | | | | | | | (15) | |
Purchase of treasury shares | | (3) | | (8,397) | | | | | | | (8,400) | |
Reduction of the B share capital | (8) | | 8 | | | | | | | | — | |
| | | | | | | | | |
Balance at the end of the period | 462 | | (3) | | 67,179 | | | | | (2,079) | | | 65,559 | |
| | | | | | | | | |
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 6: SALES SPLIT PER AREA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
Q2 2022 sales split per area | | | | | | | |
| | | | | | | |
DKK million | Total | International Operations | EMEA | Region China | Rest of World | North America Operations | The US |
| | | | | | | |
Diabetes and Obesity care segment | | | | | | | |
| Rybelsus® | 2,172 | 602 | 272 | 16 | 314 | 1,570 | 1,538 |
| % change at CER | 110% | — | — | — | — | 58% | 58% |
| Ozempic® | 14,349 | 4,170 | 2,593 | 446 | 1,131 | 10,179 | 9,341 |
| % change at CER | 75% | 88% | 57% | — | 130% | 69% | 68% |
| Victoza® | 2,710 | 1,367 | 701 | 322 | 344 | 1,343 | 1,281 |
| % change at CER | (33%) | (28%) | (29%) | (24%) | (29%) | (37%) | (38%) |
| Total GLP-1 | 19,231 | 6,139 | 3,566 | 784 | 1,789 | 13,092 | 12,160 |
| % change at CER | 45% | 47% | 32% | 65% | 80% | 44% | 42% |
| Long-acting insulin | 4,104 | 2,859 | 1,811 | 385 | 663 | 1,245 | 1,079 |
| % change at CER | (8%) | (1%) | 3% | (29%) | 13% | (22%) | (25%) |
| | Tresiba® | 2,269 | 1,493 | 871 | 228 | 394 | 776 | 642 |
| | % change at CER | (4%) | 6% | 13% | (20%) | 10% | (19%) | (24%) |
| | Xultophy® | 691 | 586 | 421 | 7 | 158 | 105 | 102 |
| | % change at CER | 4% | 9% | (1%) | — | 38% | (19%) | (19%) |
| | Levemir® | 1,144 | 780 | 519 | 150 | 111 | 364 | 335 |
| | % change at CER | (21%) | (18%) | (9%) | (42%) | (4%) | (28%) | (30%) |
| Premix insulin | 2,501 | 2,393 | 702 | 1,052 | 639 | 108 | 103 |
| % change at CER | (13%) | (13%) | (6%) | (24%) | 0% | (15%) | (15%) |
| | Ryzodeg® | 715 | 715 | 113 | 280 | 322 | — | — |
| | % change at CER | 62% | 62% | 27% | 218% | 24% | — | — |
| | NovoMix® | 1,786 | 1,678 | 589 | 772 | 317 | 108 | 103 |
| | % change at CER | (27%) | (28%) | (11%) | (40%) | (17%) | (15%) | (15%) |
| Fast-acting insulin | 3,887 | 2,609 | 1,572 | 437 | 600 | 1,278 | 1,175 |
| % change at CER | (15%) | (8%) | (5%) | (28%) | 4% | (27%) | (28%) |
| | Fiasp® | 516 | 332 | 280 | — | 52 | 184 | 173 |
| | % change at CER | 12% | 18% | 16% | — | 32% | 1% | 1% |
| | NovoRapid® | 3,371 | 2,277 | 1,292 | 437 | 548 | 1,094 | 1,002 |
| | % change at CER | (18%) | (11%) | (9%) | (28%) | 2% | (31%) | (32%) |
| Human insulin | 1,851 | 1,469 | 481 | 368 | 620 | 382 | 363 |
| % change at CER | (17%) | (22%) | (13%) | (44%) | (11%) | 18% | 22% |
| Total insulin | 12,343 | 9,330 | 4,566 | 2,242 | 2,522 | 3,013 | 2,720 |
| % change at CER | (13%) | (10%) | (3%) | (30%) | 1% | (21%) | (22%) |
| Other Diabetes care1 | 830 | 669 | 186 | 350 | 133 | 161 | 122 |
| % change at CER | (4%) | 9% | 6% | 10% | 10% | (36%) | (43%) |
| Total Diabetes care | 32,404 | 16,138 | 8,318 | 3,376 | 4,444 | 16,266 | 15,002 |
| % change at CER | 14% | 6% | 9% | (15%) | 23% | 24% | 22% |
| Wegovy® | 1,181 | 1 | 1 | — | — | 1,180 | 1,180 |
| % change at CER | — | — | — | — | — | — | — |
| Saxenda® | 2,462 | 1,286 | 789 | 41 | 456 | 1,176 | 1,057 |
| % change at CER | 19% | 57% | 65% | — | 37% | (7%) | (9%) |
| Total Obesity care | 3,643 | 1,287 | 790 | 41 | 456 | 2,356 | 2,237 |
| % change at CER | 66% | 57% | 65% | — | 37% | 72% | 77% |
| Diabetes and Obesity care total | 36,047 | 17,425 | 9,108 | 3,417 | 4,900 | 18,622 | 17,239 |
| % change at CER | 18% | 9% | 13% | (14%) | 24% | 28% | 27% |
| | | | | | | | | |
Rare disease segment | | | | | | | |
| Rare blood disorders2 | 2,863 | 1,610 | 1,022 | 87 | 501 | 1,253 | 1,145 |
| % change at CER | (3%) | 0% | 11% | 0% | (17%) | (7%) | (10%) |
| | Haemophilia A | 619 | 504 | 297 | 26 | 181 | 115 | 107 |
| | % change at CER | (6%) | 0% | (12%) | 21% | 27% | (24%) | (26%) |
| | Haemophilia B | 162 | 98 | 63 | 3 | 32 | 64 | 32 |
| | % change at CER | (4%) | 2% | (6%) | 100% | 17% | (12%) | (18%) |
| | NovoSeven® | 2,018 | 990 | 654 | 58 | 278 | 1,028 | 963 |
| | % change at CER | (2%) | 0% | 29% | (9%) | (35%) | (3%) | (7%) |
| Rare endocrine disorders3 | 1,923 | 1,286 | 587 | 60 | 639 | 637 | 631 |
| % change at CER | (2%) | 0% | (5%) | 41% | 3% | (6%) | (7%) |
| Other Rare disease4 | 432 | 241 | 198 | 2 | 41 | 191 | 106 |
| % change at CER | (3%) | (8%) | (4%) | 0% | (25%) | 7% | 2% |
| Rare disease total | 5,218 | 3,137 | 1,807 | 149 | 1,181 | 2,081 | 1,882 |
| % change at CER | (2%) | (1%) | 3% | 15% | (8%) | (5%) | (8%) |
| | | | | | | | | |
Total sales | 41,265 | 20,562 | 10,915 | 3,566 | 6,081 | 20,703 | 19,121 |
| % change at CER | 15% | 7% | 11% | (13%) | 16% | 24% | 23% |
| % change as reported | 25% | 13% | 14% | (4%) | 23% | 40% | 39% |
| Share of growth | 100% | 28% | 22% | (10%) | 16% | 72% | 64% |
1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
2) Comprises NovoSeven®, NovoEight®, Refixia®, NovoThirteen® and Esperoct®.
3) Primarily Norditropin®.
4) Primarily Vagifem® and Activelle®.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | |
H1 2022 sales split per area | | | | | | | |
| | | | | | | |
DKK million | Total | International Operations | EMEA | Region China | Rest of World | North America Operations | The US |
| | | | | | | |
Diabetes and Obesity care segment | | | | | | | |
| Rybelsus® | 4,235 | 1,115 | 546 | 23 | 546 | 3,120 | 3,063 |
| % change at CER | 134% | — | — | — | — | 88% | 88% |
| Ozempic® | 26,384 | 7,987 | 4,810 | 919 | 2,258 | 18,397 | 16,963 |
| % change at CER | 73% | 102% | 59% | — | 174% | 62% | 60% |
| Victoza® | 6,032 | 2,911 | 1,459 | 730 | 722 | 3,121 | 2,995 |
| % change at CER | (26%) | (22%) | (25%) | (14%) | (22%) | (30%) | (30%) |
| Total GLP-1 | 36,651 | 12,013 | 6,815 | 1,672 | 3,526 | 24,638 | 23,021 |
| % change at CER | 45% | 53% | 35% | 83% | 92% | 41% | 39% |
| Long-acting insulin | 8,900 | 6,020 | 3,776 | 959 | 1,285 | 2,880 | 2,565 |
| % change at CER | (6%) | 4% | 7% | (13%) | 9% | (22%) | (25%) |
| | Tresiba® | 4,833 | 3,117 | 1,788 | 557 | 772 | 1,716 | 1,462 |
| | % change at CER | 0% | 11% | 17% | 6% | 4% | (16%) | (20%) |
| | Xultophy® | 1,408 | 1,181 | 860 | 21 | 300 | 227 | 222 |
| | % change at CER | 3% | 9% | (2%) | 0% | 46% | (20%) | (20%) |
| | Levemir® | 2,659 | 1,722 | 1,128 | 381 | 213 | 937 | 881 |
| | % change at CER | (19%) | (10%) | 0% | (34%) | (8%) | (32%) | (33%) |
| Premix insulin | 5,513 | 5,242 | 1,348 | 2,602 | 1,292 | 271 | 261 |
| % change at CER | (8%) | (8%) | (11%) | (11%) | 3% | (11%) | (10%) |
| | Ryzodeg® | 1,352 | 1,352 | 243 | 512 | 597 | — | — |
| | % change at CER | 55% | 55% | 21% | — | 13% | — | — |
| | NovoMix® | 4,161 | 3,890 | 1,105 | 2,090 | 695 | 271 | 261 |
| | % change at CER | (19%) | (20%) | (16%) | (26%) | (4%) | (11%) | (10%) |
| Fast-acting insulin | 8,729 | 5,689 | 3,391 | 1,097 | 1,201 | 3,040 | 2,835 |
| % change at CER | (6%) | 0% | 2% | (14%) | 7% | (16%) | (17%) |
| | Fiasp® | 1,013 | 654 | 558 | — | 96 | 359 | 338 |
| | % change at CER | 16% | 21% | 18% | — | 45% | 7% | 6% |
| | NovoRapid® | 7,716 | 5,035 | 2,833 | 1,097 | 1,105 | 2,681 | 2,497 |
| | % change at CER | (9%) | (3%) | 0% | (14%) | 4% | (19%) | (19%) |
| Human insulin | 4,163 | 3,375 | 1,043 | 1,011 | 1,321 | 788 | 750 |
| % change at CER | (15%) | (18%) | (8%) | (32%) | (11%) | (3%) | (2%) |
| Total insulin | 27,305 | 20,326 | 9,558 | 5,669 | 5,099 | 6,979 | 6,411 |
| % change at CER | (8%) | (5%) | 1% | (17%) | 1% | (18%) | (19%) |
| Other Diabetes care1 | 1,714 | 1,331 | 361 | 691 | 279 | 383 | 310 |
| % change at CER | (16%) | (11%) | 3% | (25%) | 15% | (29%) | (33%) |
| Total Diabetes care | 65,670 | 33,670 | 16,734 | 8,032 | 8,904 | 32,000 | 29,742 |
| % change at CER | 15% | 10% | 12% | (7%) | 25% | 21% | 20% |
| Wegovy® | 2,585 | 1 | 1 | — | — | 2,584 | 2,584 |
| % change at CER | — | — | — | — | — | — | — |
| Saxenda® | 4,460 | 2,479 | 1,515 | 78 | 886 | 1,981 | 1,761 |
| % change at CER | 21% | 60% | 78% | — | 29% | (8%) | (11%) |
| Total Obesity care | 7,045 | 2,480 | 1,516 | 78 | 886 | 4,565 | 4,345 |
| % change at CER | 84% | 60% | 78% | — | 29% | 102% | 110% |
| Diabetes and Obesity care total | 72,715 | 36,150 | 18,250 | 8,110 | 9,790 | 36,565 | 34,087 |
| % change at CER | 19% | 12% | 16% | (6%) | 25% | 27% | 27% |
| | | | | | | | | |
Rare disease segment | | | | | | | |
| Rare blood disorders2 | 5,940 | 3,413 | 1,907 | 184 | 1,322 | 2,527 | 2,357 |
| % change at CER | 3% | 3% | (7%) | 69% | 16% | 3% | 2% |
| | Haemophilia A | 1,184 | 953 | 580 | 43 | 330 | 231 | 217 |
| | % change at CER | 1% | 6% | (7%) | 95% | 35% | (16%) | (17%) |
| | Haemophilia B | 339 | 216 | 133 | 6 | 77 | 123 | 61 |
| | % change at CER | 6% | 15% | 2% | — | 38% | (7%) | 2% |
| | NovoSeven® | 4,289 | 2,203 | 1,170 | 135 | 898 | 2,086 | 1,997 |
| | % change at CER | 3% | 1% | (8%) | 58% | 9% | 6% | 5% |
| Rare endocrine disorders3 | 3,743 | 2,504 | 1,140 | 109 | 1,255 | 1,239 | 1,227 |
| % change at CER | (5%) | (1%) | (4%) | 43% | 0% | (14%) | (14%) |
| Other Rare disease4 | 898 | 536 | 442 | 4 | 90 | 362 | 203 |
| % change at CER | 7% | (2%) | 0% | 50% | (14%) | 27% | 37% |
| Rare disease total | 10,581 | 6,453 | 3,489 | 297 | 2,667 | 4,128 | 3,787 |
| % change at CER | 0% | 1% | (5%) | 58% | 7% | (1%) | (2%) |
| | | | | | | | | |
Total sales | 83,296 | 42,603 | 21,739 | 8,407 | 12,457 | 40,693 | 37,874 |
| % change at CER | 16% | 10% | 12% | (5%) | 21% | 24% | 23% |
| % change as reported | 25% | 15% | 14% | 4% | 27% | 36% | 36% |
| Share of growth | 100% | 35% | 20% | (4%) | 19% | 65% | 58% |
1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
2) Comprises NovoSeven®, NovoEight®, Refixia®, NovoThirteen® and Esperoct®.
3) Primarily Norditropin®.
4) Primarily Vagifem® and Activelle®.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 7: ACQUISITION OF BUSINESSES
On 28 December 2021, Novo Nordisk acquired all outstanding shares of the publicly held US company Dicerna Pharmaceuticals, Inc. via a cash tender offer. Before the acquisition, Novo Nordisk held 2.9% of the shares in Dicerna Pharmaceuticals, Inc. at a fair value of DKK 573 million.
Details of the acquisition
The total purchase price amounts to DKK 22,034 million, which has been settled by the fair value of existing shareholdings of DKK 573 million, settlement of a pre-existing relationship of DKK 145 million and a cash consideration of DKK 21,316 million.
No changes have been made during the first 6 months of 2022 to the provisional purchase price allocation as presented in the 2021 Annual Report note 5.3. Acquisition of businesses.
The development in goodwill in the six months of 2022 is as follows:
| | | | | |
DKK million | 30 Jun 2022 |
Goodwill as of 31 December 2021 | 4,346 |
Exchange rate adjustment | 395 |
Goodwill as of 30 June 2022 | 4,741 |
For further information regarding the acquisition please refer to the Annual Report for 2021.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
APPENDIX 8: NON-IFRS FINANCIAL MEASURES (ADDITIONAL INFORMATION)
In this Company Announcement, Novo Nordisk discloses certain financial measures of the Group’s financial performance, financial position and cash flows that reflect adjustments to the directly comparable measures calculated and presented in accordance with IFRS. These non-IFRS financial measures may not be defined and calculated by other companies in the same manner and may thus not be comparable with such measures. The non-IFRS financial measures presented in the Company Announcement are Sales and operating profit at CER, Free cash flow and Financial reserves.
Sales and operating profit growth at CER
'Growth at CER’ means that the effect of changes in exchange rates is excluded. It is defined as Net sales/Operating profit for the period measured at the average exchange rates for the same period prior year compared with Net sales/Operating profit for the same period prior year. Price adjustments within hyperinflation countries as defined in IAS 29 ‘Financial reporting in hyperinflation economies’ are excluded from the calculation to avoid growth at CER being artificially inflated.
Growth at CER is considered to be relevant information for investors in order to understand the underlying development in sales and operating profit by adjusting for the impact of currency fluctuations.
| | | | | | | | | | | | | | | | | | | | | | | |
Sales at CER | | | | | | | |
| | | | | | | |
DKK million | H1 2022 | H1 2021 | % change H1 2022 to H1 2021 | | Q2 2022 | Q2 2021 | % change Q2 2022 to Q2 2021 |
| | | | | | | |
Net sales | 83,296 | | 66,845 | | 25 | % | | 41,265 | | 33,041 | | 25 | % |
Effect of exchange rates | (5,511) | | — | | | | (3,350) | | — | | |
Sales at CER | 77,785 | | 66,845 | | 16 | % | | 37,915 | | 33,041 | | 15 | % |
| | | | | | | |
Operating profit at CER | | | | | | | |
| | | | | | | |
DKK million | H1 2022 | H1 2021 | % change H1 2022 to H1 2021 | | Q2 2022 | Q2 2021 | % change Q2 2022 to Q2 2021 |
| | | | | | | |
Operating profit | 37,538 | | 29,761 | | 26 | % | | 18,391 | | 14,779 | | 24 | % |
Effect of exchange rates | (3,602) | | — | | | | (2,162) | | — | | |
Operating profit at CER | 33,936 | | 29,761 | | 14 | % | | 16,229 | | 14,779 | | 10 | % |
Free cash flow
Novo Nordisk defines free cash flow as ’net cash generated from operating activities’, less ‘net cash used in investing activities’, less repayment on lease liabilities and excluding net change of marketable securities. Free cash flow is a measure of the amount of cash generated in the period which is available for the Board of Directors to allocate between Novo Nordisk's capital providers, through eg dividends, share repurchases and repayment of debt (excluding lease liability repayments) or for retaining in the business to fund future growth.
The following table shows a reconciliation of Free cash flow with Net cash generated from operating activities, the most directly comparable IFRS financial measure:
| | | | | | | | | | | | | | |
Free cash flow | | | | |
| | | | |
DKK million | H1 2022 | H1 2021 | Q2 2022 | Q2 2021 |
| | | | |
Net cash generated from operating activities | 47,547 | | 36,510 | | 23,961 | | 25,255 | |
Net cash used in investing activities | (6,107) | | (6,367) | | (4,200) | | (2,886) | |
Net purchase of marketable securities | 1,745 | | 2,987 | | 1,625 | | 1,004 | |
| | | | |
Repayment on lease liabilities | (460) | | (434) | | (229) | | (209) | |
Free cash flow | 42,725 | | 32,696 | | 21,157 | | 23,164 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
| | | | | |
Financial report for the period 1 January 2022 to 30 June 2022 | |
Financial reserves
'Financial reserves' is defined as the sum of cash and cash equivalents at the end of the period, marketable securities with original term to maturity exceeding three months and undrawn committed credit and loan facilities, with a maturity of more than 12 months, less loans and bank overdrafts classified as liabilities arising from financing activities with obliged repayment within 12 months of the balance sheet date. The following table reconciles total financial reserves with cash and cash equivalents, the most directly comparable IFRS financial measure:
| | | | | | | | |
Financial reserves | | |
| | |
DKK million | H1 2022 | H1 2021 |
| | |
Cash and cash equivalents | 22,756 | | 24,227 | |
Marketable securities | 8,279 | | 2,987 | |
Undrawn committed credit facility | 11,531 | | 11,526 | |
| | |
Borrowings | (389) | | (525) | |
Financial reserves | 42,177 | | 38,215 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information |
| | | | | Company announcement No 61 / 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: August 3, 2022
Novo Nordisk A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024